Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma

British Journal of Surgery

Volumn 85, Issue 1, 1998, Pages 46-51

  Ross, D A ^a   Wilson, G D ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; ONCOPROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; MALE; MELANOMA; ONCOGENE C MYC; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-MYC; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0031973401     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.1998.00528.x     Document Type: Article

References (32)

1. Koh HK. Cutaneous melanoma. N Engl J Med 1991; 325: 171-82.
2. Breslow A. Thickness, cross-sectional area and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172: 902-8.
3. Blessing K, McLaren KM, McLean A, Davidson P. Thin malignant melanomas (less than 1·5 mm) with metastasis: a histological study and survival analysis. Histopathology 1990; 17: 389-95.
4. Albino AP. Genes involved in melanoma susceptibility and progression. Curr Opin Oncol 1995; 7: 162-9.
5. Bishop JM. Molecular themes in oncogenesis. Cell 1991; 64: 235-48.
6. Littlewood TD, Evan GI. The role of myc oncogenes in cell growth and differentiation. Advances in Dental Research 1990; 4: 69-79.
7. Evan GI, Littlewood TD. The role of c-myc in cell growth. Curr Opin Genet Dev 1993; 3: 44-9.
8. Evan GI, Wyllie AH, Gilbert CS et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 63: 119-28.
9. Lu X, Park SH, Thompson TC, Lane DP. ras-induced hyperplasia occurs with mutation of p53, but activated ras and mvc together can induce carcinoma without p53 mutation. Cell 1992; 70: 153-61.
10. Garte SJ. The c-myc oncogene in tumor progression. Crit Rev Oncog 1993; 4: 435-49.
11. Bourhis J, Le MG, Barrois M et al. Prognostic value of c-myc proto-oncogene overexpression in early invasive carcinoma of the cervix. J Clin Oncol 1990; 8: 1789-96.
12. Field JK, Spandidos DA, Stell PM, Vaughn ED, Evan GI, Moore JP. Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene 1989; 4: 1463-8.
13. Lazaris AC, Theodoropoulos GE, Aroni K, Saetta A, Davaris PS. Immunohistochemical expression of c-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma. Virchows Arch 1995; 426: 461-7.
14. Watson JV. Nuclear associated antigens. In: Ormerod MG, ed. Flow Cytometry; A Practical Approach. 2nd ed. Oxford: IRL Press, 1995: 209-28.
15. Kaplan EL, Meier P. Non-parametric estimation for incomplete investigations. Journal of the American Statistical Association 1958; 53: 457-81.
16. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
17. Cox DR. Regression models and life tables. Journal of the Royal Statistical Association 1972; 34: 187-220.
18. Balch CM, Soong S, Shaw HM, McCarthy WH. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, ed. Cutaneous Melanoma. Philadelphia, Pennsylvania: JB Lippincott, 1992: 165-87.
19. Slingluff CL Jr, Vollmer RT, Reinigen DS, Seigler HF. Lethal 'thin' malignant melanoma. Identifying patients at risk. Ann Surg 1988; 208: 150-61.
20. Cascinelli N, Vaglini M, Nava M et al. Prognosis of skin melanoma with regional node metastases (stage 2). J Surg Oncol 1984; 25: 240-7.
21. Kissin MW, Simpson DA, Easton D, White H, Wcsthury G. Prognostic factors related to survival and groin recurrence following therapeutic lymph node dissection for lower limb malignant melanoma. Br J Surg 1987; 74: 1023-6.
22. Balch CM, Soong S-J, Murad TM, Ingalls AL, Maddox WA. A multi-factorial analysis of melanoma: 3. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 1981; 193: 377-88.
23. van't Veer LJ, Burgering BMT, Versteeg R et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol 1989; 9: 3114-16.
24. Trent JM, Meyskens FL, Salmon SE et al. Relation of cytogenctic abnormalities and clinical outcome in metastatic melanoma. N Engl J Med 1990; 322: 1508-11.
25. Fountain JW, Karayiorgou M, Ernstoff MS et al. Homozygous deletions within human chromosome hand 9p21 in melanoma. Proc Natl Acad Sci U S A 1992; 89: 10557-61.
26. Coleman A, Fountain JW, Nobori T et al. Distinct deletions of chromosome 9p associated with melanoma versus glioma, lung cancer, and leukaemia. Cancer Res 1994; 54: 344-8.
27. Berns EMJJ, Klijn JGM, van Putten WLJ, van Staveren IL, Portengen H, Foekens JA. c-myc amplification is a better prognostic factor than Her2/neu amplification in primary breast cancer. Cancer Res 1992; 52: 1107-13.
28. Masters JRW, Vesey SG, Munn CF, Evan GI, Watson JV. c-myc oncoprotein levels in bladder cancer. Urol Res 1988; 16: 341-4.
29. Seeger RC, Brodeur GM, Sather H et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111-16.
30. Husain Z, FitzGerald GB, Wick MM. Comparison of cellular proto-oncogene activation and transformation-related activity of human melanocytes and metastatic melanoma. J Invest Dermatol 1990; 95: 571-5.
31. Chevenix-Trench G, Martin NG, Ellem KAO. Gene expression in melanoma cell lines and cultured melanocytes: correlation between levels of c-src-1, c-myc and p53. Oncogene 1990; 5: 1187-93.
32. Hart IR, Easty D. Tumor cell progression and differentiation in metastasis. Semin Cancer Biol 1991; 2: 87-95.